Compare ECOR & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ECOR | TENX |
|---|---|---|
| Founded | 2005 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.1M | 56.2M |
| IPO Year | 2018 | 2001 |
| Metric | ECOR | TENX |
|---|---|---|
| Price | $7.16 | $12.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $18.00 | ★ $29.67 |
| AVG Volume (30 Days) | 52.1K | ★ 575.9K |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $32,032,000.00 | N/A |
| Revenue This Year | $33.60 | N/A |
| Revenue Next Year | $30.40 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 27.20 | N/A |
| 52 Week Low | $4.16 | $5.34 |
| 52 Week High | $8.30 | $18.38 |
| Indicator | ECOR | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 63.43 | 42.00 |
| Support Level | $4.55 | $10.83 |
| Resistance Level | $7.50 | $14.15 |
| Average True Range (ATR) | 0.48 | 1.07 |
| MACD | 0.09 | -0.19 |
| Stochastic Oscillator | 90.60 | 4.73 |
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.